BC Week In Review | Apr 15, 2013
Company News

Zynaxis, ProClinical deal

ZNXS will sell its Cauldron Process Chemistry division to ProClinical for $850,000. Cauldron provides R&D and pilot scale bulk pharmaceutical manufacturing services. ProClinical is a contract services company specializing in clinical supplies manufacturing, packaging and...
BC Week In Review | Aug 18, 1997
Company News

Delsys management update

Delsys Pharmaceutical Corp., Princeton, N.J.   Business: Drug delivery   Hired: Martyn Greenacre, formerly CEO of Zynaxis Inc. , as president and CEO; Charles Reinhart, formerly director of finance and administration at GenVec Inc. , as VP...
BC Week In Review | Jun 23, 1997
Company News

Vaxcel, ProClinical Inc. deal

VXCL, which began trading on June 16 as a result of Vaxcel's merger with Zynaxis Inc. (Malvern, Penn.), completed the sale of Zynaxis's Cauldron Process Chemistry Division to ProClinical. Cauldron provides R&D and pilot scale...
BC Week In Review | Apr 28, 1997
Company News

CytRx, Zynaxis infectious diseases/aids news

CYTR's shareholders will vote on May 21 on the proposed merger of ZNXS and CYTR's Vaxcel Inc. (Atlanta, Ga.) subsidiary, which develops vaccine delivery systems (see BioCentury Dec. 9, 1996). CytRx Corp. (CYTR), Norcross, Ga....
BC Week In Review | Mar 3, 1997
Clinical News

CRL-1005 Optivax copolymer data

Vaxcel, a subsidiary of CytRx Corp. (CYTR, Atlanta, Ga.), announced that a Phase I trial has shown safety and adjuvant action of the Optivax copolymer, when given with a beta human chorionic gonadotropin (BhGC) vaccine....
BC Week In Review | Feb 10, 1997
Company News

Phanos Technologies Inc., Zynaxis deal

ZNXS will sell its Zyn-Linker drug delivery technology to Phanos for $725,000. The sale does not affect ZNXS's December 1996 plan to merge with Vaxcel Inc. (Atlanta, Ga.) to create a publicly held vaccine delivery...
BC Week In Review | Dec 9, 1996
Company News

CytRx, Zynaxis deal

The companies agreed to merge ZNXS with CYTR's Vaxcel Inc. subsidiary. The combined company, which will be publicly traded, will include Vaxcel's Optivax adjuvant to enhance the effectiveness of injectable vaccines, and ZNXS's technology for...
BC Week In Review | Sep 23, 1996
Company News

Zynaxis infectious diseases/aids, drug delivery news

ZNXS cut its work force to 18 from 40 employees following the withdrawal of Seloc AG from negotiations to purchase ZNXS's Cauldron Process Chemistry Division (see BioCentury Sept. 3). ZNXS had $168,000 in cash as...
BC Week In Review | Sep 3, 1996
Company News

Zynaxis, Seloc AG deal

The companies terminated their letter of intent under which ZNXS was planning to sell its Cauldron Process Chemistry division to Seloc AG, a Schwarz Pharma subsidiary, for an undisclosed amount (see BioCentury July 22). ZNXS...
BC Week In Review | Aug 26, 1996
Company News

Zynaxis other research news

ZNXS published the use of its Zyn-linker technology to create membrane anchored, pH sensitive compounds that are internalized into cells and slowly release active drug. As reported in The Journal of Controlled Release, mice with...
Items per page:
1 - 10 of 38
BC Week In Review | Apr 15, 2013
Company News

Zynaxis, ProClinical deal

ZNXS will sell its Cauldron Process Chemistry division to ProClinical for $850,000. Cauldron provides R&D and pilot scale bulk pharmaceutical manufacturing services. ProClinical is a contract services company specializing in clinical supplies manufacturing, packaging and...
BC Week In Review | Aug 18, 1997
Company News

Delsys management update

Delsys Pharmaceutical Corp., Princeton, N.J.   Business: Drug delivery   Hired: Martyn Greenacre, formerly CEO of Zynaxis Inc. , as president and CEO; Charles Reinhart, formerly director of finance and administration at GenVec Inc. , as VP...
BC Week In Review | Jun 23, 1997
Company News

Vaxcel, ProClinical Inc. deal

VXCL, which began trading on June 16 as a result of Vaxcel's merger with Zynaxis Inc. (Malvern, Penn.), completed the sale of Zynaxis's Cauldron Process Chemistry Division to ProClinical. Cauldron provides R&D and pilot scale...
BC Week In Review | Apr 28, 1997
Company News

CytRx, Zynaxis infectious diseases/aids news

CYTR's shareholders will vote on May 21 on the proposed merger of ZNXS and CYTR's Vaxcel Inc. (Atlanta, Ga.) subsidiary, which develops vaccine delivery systems (see BioCentury Dec. 9, 1996). CytRx Corp. (CYTR), Norcross, Ga....
BC Week In Review | Mar 3, 1997
Clinical News

CRL-1005 Optivax copolymer data

Vaxcel, a subsidiary of CytRx Corp. (CYTR, Atlanta, Ga.), announced that a Phase I trial has shown safety and adjuvant action of the Optivax copolymer, when given with a beta human chorionic gonadotropin (BhGC) vaccine....
BC Week In Review | Feb 10, 1997
Company News

Phanos Technologies Inc., Zynaxis deal

ZNXS will sell its Zyn-Linker drug delivery technology to Phanos for $725,000. The sale does not affect ZNXS's December 1996 plan to merge with Vaxcel Inc. (Atlanta, Ga.) to create a publicly held vaccine delivery...
BC Week In Review | Dec 9, 1996
Company News

CytRx, Zynaxis deal

The companies agreed to merge ZNXS with CYTR's Vaxcel Inc. subsidiary. The combined company, which will be publicly traded, will include Vaxcel's Optivax adjuvant to enhance the effectiveness of injectable vaccines, and ZNXS's technology for...
BC Week In Review | Sep 23, 1996
Company News

Zynaxis infectious diseases/aids, drug delivery news

ZNXS cut its work force to 18 from 40 employees following the withdrawal of Seloc AG from negotiations to purchase ZNXS's Cauldron Process Chemistry Division (see BioCentury Sept. 3). ZNXS had $168,000 in cash as...
BC Week In Review | Sep 3, 1996
Company News

Zynaxis, Seloc AG deal

The companies terminated their letter of intent under which ZNXS was planning to sell its Cauldron Process Chemistry division to Seloc AG, a Schwarz Pharma subsidiary, for an undisclosed amount (see BioCentury July 22). ZNXS...
BC Week In Review | Aug 26, 1996
Company News

Zynaxis other research news

ZNXS published the use of its Zyn-linker technology to create membrane anchored, pH sensitive compounds that are internalized into cells and slowly release active drug. As reported in The Journal of Controlled Release, mice with...
Items per page:
1 - 10 of 38